# Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine Coadministered With Two Attenuated Vaccines

> **NCT05952505** · PHASE4 · UNKNOWN · sponsor: **Shanghai Municipal Center for Disease Control and Prevention** · enrollment: 540 (estimated)

## Conditions studied

- SARS-CoV-2 Infection
- Varicella
- Measles
- Mumps
- Rubella

## Interventions

- **BIOLOGICAL:** Inactivated SARS-CoV-2 vaccine coadministered with vricella vaccine
- **BIOLOGICAL:** Inactivated SARS-CoV-2 vaccine coadministered with MMR
- **BIOLOGICAL:** Inactivated SARS-CoV-2 vaccine administered alone

## Key facts

- **NCT ID:** NCT05952505
- **Lead sponsor:** Shanghai Municipal Center for Disease Control and Prevention
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-08
- **Primary completion:** 2023-12
- **Final completion:** 2024-12
- **Target enrollment:** 540 (ESTIMATED)
- **Last updated:** 2023-07-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05952505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05952505, "Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine Coadministered With Two Attenuated Vaccines". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT05952505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*